Expansion of the women's health business through the acquisition of Yucora
First written in FY2021-Q3. 8 of 9 entries say "Advanced", first in FY2021. Latest entry: 2026-04-28.
No other company in this theme has enough history to compare yet.
- 2026-04-28AdvancedEarnings
「In Japan, revenue from Equelle increased as awareness expanded through educational activities and seminars focused on women’s health, contributing to the acquisition of new customers.」
In the women’s health category, the company cited expanded awareness through educational activities and other initiatives, as well as new customer acquisition, as factors behind the increase in revenue. - FY2025AdvancedAnnual report
「As a result, revenue in this category was ¥60,800 million, up 7.4% from the previous fiscal year.」
In the women's health category, revenue increased 7.4% from the previous fiscal year due to the rollout of Bonafide Health's SARMELA, Equelle and other products. - FY2025-H1AdvancedAnnual report
「As a result, revenue in this category was ¥29,034 million, up 7.8% year on year.」
In the women's health category, revenue increased 7.8% year on year due to higher awareness and promotional activities for Yocera, Bonafide, SARMELA and Equelle. - FY2024AdvancedAnnual report
「As a result, revenue in this category was ¥56,613 million, up 52.3% from the previous fiscal year.」
In the women's health category, Equelle, Yocera and Bonafide were rolled out, resulting in a 52.3% year-on-year increase in revenue. - FY2024-H1AdvancedAnnual report
「Equelle, an equol-containing food supporting women's health and beauty, recorded higher revenue. In Japan, product awareness is increasing through broad information activities, including women's health seminars. In the United States, e-commerce is expanding. Yocera, which supports women's urinary health, recorded higher revenue as in-store pharmacy sales progressed steadily in addition to e-commerce growth. In this category, the acquisition of Bonafide Health in November 2023, which supports women's health, added its Bonafide brand to the portfolio. As a result, revenue in this category was ¥26,926 million, up 56.9% year on year.」
In the women's health category, Equelle, Yocera and Bonafide expanded, resulting in a 56.9% year-on-year increase in revenue. The acquisition of Bonafide Health and the subsequent addition and sales expansion of its brand are described in specific terms. - FY2024-Q1AdvancedAnnual report
「In the nutraceuticals-related business, revenue increased as Pocari Sweat and Nature Made continued to grow amid heightened health awareness, and Bonafide Health, acquired in November 2023, was added to the business.」
Bonafide Health, acquired in November 2023, was added to the nutraceuticals-related business and contributed to higher revenue. - FY2023AdvancedAnnual report
「Pharmavite LLC, our consolidated subsidiary, entered into an agreement to acquire all shares of Bonafide Health LLC, which manufactures and sells products specializing in women's health, and completed the acquisition on 30 November 2023.」
Following Yocera and Equelle, Bonafide Health was acquired, expanding the health food business for women. - FY2021AdvancedAnnual report
「In the women's health field, we acquired Yocera in North America in July 2021. The company has strengths in products and platforms specializing in women's urinary health.」
The acquisition of Yocera was completed, and R&D and product rollout in women's health leveraging synergies within the Group are advancing. - FY2021-Q3First statedAnnual report
「In the women's health field, we acquired Yocera in North America in July this year. The company has strengths in products and platforms specializing in women's urinary health. We will promote R&D to provide broader and more comprehensive support for women's health in this field, where unmet needs are high, by leveraging synergies within the Group.」
Yocera, which has strengths in products and platforms for women's urinary health in North America, was acquired in July 2021, and a new R&D initiative in women's health leveraging synergies within the Group has been established.